Dipexium’s and Innocoll’s Antibacterial Candidates for Diabetic Foot Infection Flop in Q4 of 2016
22 Dec 2016
Diabetic foot infections (DFIs) are a common complication of diabetic foot ulcers (DFUs), with an estimated prevalence of 58% among all diagnosed DFU patients. If left untreated, DFIs can cause osteomyelitis, severe sepsis, and a risk of amputation. Ischemic and chronic ulcers carry an increased risk of infections that are composed of multiple bacterial species, along with an increased risk of these polymicrobial communities displaying reduced susceptibility towards multiple antibiotics. Despite the availability of various antibiotics, including Pfizer’s Zyvox (linezolid) and Merck’s Invanz (ertapenem), both indicated for DFIs, there remains the need for additional therapies to help address hard-to-treat DFIs. In an attempt to meet this unmet need, Dipexium Pharmaceuticals and Innocoll were developing two topical antibacterial candidates, Locilex (pexiganan) and Cogenzia (gentamicin-collagen sponge), respectively.
Registering for our Expert Insights is free and only takes a moment.
Following this you'll gain unlimited access to all of the latest, event-driven opinion
put together by our teams of experienced analysts.